Citric acid Mosabily oral liquid

A technology of mosapride citrate and oral solution, applied in the directions of drug delivery, digestive system, organic active ingredients, etc., can solve problems such as inability to apply, and achieve improved bioavailability, guaranteed stability, and high dispersity. Effect

Active Publication Date: 2006-11-01
LUNAN PHARMA GROUP CORPORATION
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The Chinese patent application number 01133743.5 discloses a pharmaceutical formulation of mosapride citrate suitable for preparing dispersible tablets by wet granulation and tabletting method. This formulation is suitable for preparing dispersible tablets, but cannot be applied to Other dosage forms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Mosapride Citrate 50mg

[0017] Ethanol 5ml

[0018] Propylene glycol 5ml

[0019] Sucrose 60g

[0020] Sodium Benzoate 1.2g

[0021] Methylparaben 2.5g

[0022] Flavor 0.5g

[0023] Add water to 1000ml

[0024] Preparation process: Place the prescribed amount of ethanol and propylene glycol in a suitable container, add the prescribed amount of mosapride citrate, heat it in a water bath to dissolve, and then dissolve other additives in the prescribed amount with a small amount of water, and then add them to the above-mentioned Add water to the mixed solution containing medicine, stir evenly, adjust the pH value with hydrochloric acid or sodium hydroxide solution to make it between 3.0 and 4.5, filter, pack and sterilize.

Embodiment 2

[0026] Mosapride Citrate 25mg

[0027] Polyethylene Glycol-300 200ml

[0028] Sucrose 70g

[0029] Ethylparaben 1.5g

[0030] Add water to 1000ml

[0031] The preparation process is the same as in Example 1.

Embodiment 3

[0033] Mosapride Citrate 200mg

[0034] Polyethylene Glycol-300 300ml

[0035] Aspartame 10g

[0036] Add water to 1000ml

[0037] The preparation process is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An orally taken solution of mosapride citrate is prepared from mosapride citrate, glycerin, alcohol, propanediol, polyethanediol-300, polyethanediol-400, antisetic and flavouring. It has fast absorption rate and high stability.

Description

technical field [0001] The invention belongs to the technology of western medicine preparation. Background technique [0002] Mosapride citrate (Mosapride Citrate) is a new third-generation gastric motility drug, mainly used for the treatment of esophageal reflux disease. The drug can enhance gastrointestinal motility, but does not affect gastric acid secretion, and has no side effects such as extrapyramidal reaction and diarrhea, and is well tolerated. Mosapride citrate is the first selective 5-HT 4 Receptor agonist, which is a benzamide derivative, stimulates 5-HT in the myenteric plexus 4 Receptors, increase the release of acetylcholine from nerve endings, promote gastrointestinal motility and gastric emptying, have strong receptor selectivity, and selectively act on 5-HT 4 receptors, and thus does not antagonize dopamine D compared to metoclopramide 2 Central nervous system side effects caused by receptors, extrapyramidal system reactions and side effects caused by a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/535A61K9/08A61P1/04A61P1/08A61P1/14
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap